News

"We are very pleased to receive Fast Track Designation for Betalutin in marginal zone lymphoma, which recognizes the clear need for new therapeutic options for patients with advanced marginal zone lymphoma patients who no longer respond to the therapies they have been receiving."

In a single-institution study, investigators found a correlation between certain genotypes and comorbidities and trastuzumab-induced cardiotoxicity among patients with HER2-positive breast cancer.

Targeted Oncology reviews trending news online for the week of June 26, 2020, including recent news from the FDA, updates in oncology, and new information regarding COVID-19.

In an interview with Targeted Oncology, John P. Leonard, MD, discussed the results of the phase 2 study of tazemetostat, the drug approval for relapsed/refractory follicular lymphoma, and the role of tazemetostat in the community setting.

TXR-311 has demonstrated activity in validation studies and has selectivity for killing hepatocellular carcinoma tumor cells.

"This interim clinical and translational data add further confidence to the potential patient benefit of selective AXL inhibition with bemcentinib, to reverse resistance to immune checkpoint inhibitors in selected cAXL-positive patients who have relapsed on immunotherapy."

In an interview with Targeted Oncology, Anthony Mato, MD, discussed the findings of venetoclax interruptions or discontinuations observed in patients with relapsed/refractory chronic lymphocytic leukemia who received the combination of venetoclax plus rituximab in the phase 3 MURANO study.

All patients with relapsed/refractory chronic lymphocytic leukemia should be evaluated for both complex karyotypes and del17p prior to initiating treatment, and all patients with complex karyotypes should be considered candidates for alternative combination therapy.

Liso-cel administration in the outpatient setting was implemented successfully in 3 clinical trials at academic and nonacademic medical centers.

Pembrolizumab received FDA approval for the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma that cannot be cured by either surgery or radiation.

“Cervical cancer screening rates are suboptimal among Asian American women, despite considerable efforts to improve Pap test screening."

If validated, the investigators believe that this non-invasive test could help detect renal cell carcinoma earlier on, thereby reducing the mortality of the disease.

The phase 2 TELLOMAK clinical trial is no longer on a partial clinical hold. As a result, trial enrollment with continue in patient with advanced T-cell lymphomas.

The website Project Patient Voice has been launched by the FDA, which is a new website that will share publicly available information on patient-reported outcomes from clinical trials for cancer.

Patients receiving high-dose therapy for mantle cell lymphoma are at a higher risk of treatment failure if they have mutations in the TP53 or KMT2D genes, according to new research.

MET amplifications are found in up to 10% of patients with EGFR-mutant NSCLC who progress on first- or second-generation EGFR TKIs and in up to 25% of those who progress on a third-generation EGFR TKIs, necessitating the need for treatment options in the population.

With a Fast Track designation, the development of seviprotimut-L will be facilitated and expeditiously reviewed by the FDA to address an unmet medical need for patients with stage IIB and IIIC melanoma,

"As the first FDA-approved therapy to treat this debilitating disease, today’s action is an important step in finding treatment options for patients living with tumor-induced osteomalacia whose tumor cannot be found or removed."

"When compared to ibrutinib, TG-1701 used at high doses retained notable antitumor activity in MCL cells with BTK C481S mutation, while it did not show superior activity than the first-in-class BTK [inhibitor] in in vitro and in vivo models of ibrutinib-resistant MCL with constitutive activation of the non-canonical NF-KB pathway.”

"The iNNOVATE study continues to deliver strong clinical evidence supporting the long-term use of ibrutinib plus rituximab across first and second lines of therapy for patients with Waldenström's macroglobulinemia."

In an interview with Targeted Oncology, Prasad S. Adusumilli, MD, FACS, discussed how CAR T-cell therapy could play a role in the treatment of solid tumors. He highlighted the current research and next steps planned to move this cellular therapy into the solid tumor treatment landscape.

These data suggest that screening for pulmonary hypertension is warranted in patients with a Philadelphia chromosome-negative myeloproliferative neoplasm, both at the time of diagnosis and during follow-up.

In an interview with Targeted Oncology, Michael Schuster, MD, discussed the findings in the phase 2 SADAL study and the importance of the FDA approval of selinexor for the treatment of relapsed/refractory diffuse large B-cell lymphoma.

Oral relugolix received a priority review designation from the FDA for the treatment of patients with advanced prostate cancer.

The FDA has announced plans to convene a meeting of the Oncologic Drugs Advisory Committee to review the Biologic License Application for belantamab mafodotin as treated of patients with relapsed or refractory multiple myeloma.

Selinexor is now the only single-agent, oral therapy approved for the treatment of patients with R/R DLBCL, and the only nuclear export inhibitor approved by the FDA for use in 2 hematologic malignancies, multiple myeloma and DLBCL.

“RO7198457 in combination with atezolizumab induced immune responses in the majority of patients, including preliminary data demonstrating the detection of neoantigen-specific T-cell responses within the tumor."

“[This] report on the diagnosis of blood cancers in the US/Mexico border inure the different frequency of leukemia subtypes and their outcomes, highlighting important health disparities due to different access to diagnosis and care due to a series of factors."